☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

EMA reviewing pioglitazone safety

The European Medicines Agency (EMA) has announced (PDF) that it is conducting a safety review of pioglitazone containing medicines. The Food and Drugs Administration (FDA) is conducting a similar review.

This review is being conducted as a result of a recently completed French study which found an increased risk of bladder cancer. The French authorities have suspended the product license as a result of this finding pending a full review.

The results of the review are expected to be available in July. The EMA also state that the association between bladder cancer and pioglitazone use has been under continuous review since the product license was granted in 2000. Three previous reviews have failed to confirm a clear association but have indicated a potential increased risk in those with longest exposure and highest cumulative dose.

Action: Clinicians should be aware of this review. It would be prudent to avoid initiating new treatment with pioglitazone until the review is completed. Patients currently taking pioglitazone who are concerned about the potential increase in risk could be reviewed and have their treatment changed if this will maintain patient-clinician trust.

Share 'EMA reviewing pioglitazone safety' by emailShare 'EMA reviewing pioglitazone safety' on FacebookShare 'EMA reviewing pioglitazone safety' on TwitterShare 'EMA reviewing pioglitazone safety' on LinkedInShare 'EMA reviewing pioglitazone safety' on reddit


One Comment to “EMA reviewing pioglitazone safety”

  1. This is an interesting piece! Actos is a terrible drug that should be banned in the United States. This is because, it causes bladder cancer and other serious side effects. This is a great resource:


    Comment by Chris Jackson — July 15, 2011 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.